Market Research Logo

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2018.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.

Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.

Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 provides the reader with the following key benefits:

In-depth understanding of royalty rate partnering deal trends since 2010
Analysis of the structure of royalty clauses with numerous real life case studies
Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 includes:

Trends in royalty rates in the biopharma industry since 2010
Analysis of royalty rate clause structure
Case studies of real-life licensing deals which disclose royalty rates
Comprehensive listing of licensing deals which disclose royalty rates since 2010
Access to licensing contract documents which disclose royalty rates
The leading licensing deals by royalty rate value since 2010
Most active royalty rate disclosures since 2010

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


  • Executive Summary
  • Introduction
    • What are royalties?
    • History of royalty rates
    • Royalties in pharma and biotech
    • Royalties versus revenue share
    • Overview of the report
  • An overview of pharma and biotech royalty rates
    • Trends in royalty rates 2010- 2018
    • How do revenue shares figure?
    • A review of recent literature
    • Royalty rates in the future
  • Average royalty rates for pharma and biotech partnering
    • Royalty rates in early stage deals
    • Royalty rates by stage of development
    • Royalty rates by therapy area
  • The royalty clause in pharma and biotech deals
    • Partnering agreement structure
      • Table Components of the partnering deal structure
    • Structure of a typical royalty clause
      • Table Components of the partnering royalty clause
    • Example royalty clauses
      • Merck Serono-Opexa Therapeutics
      • Aradigm - Grifols
      • Forect Laboratories - Trevena
      • Sage Therapeutics - University of California
  • Companies actively disclosing royalty rates
    • Most active companies in disclosing royalty rates
      • AstraZeneca
      • Israeli National Authority for Technological Innovation
      • Intrexon
      • Ligand Pharmaceuticals
      • ContraFect
      • TrovaGene
      • Celgene
      • Genentech
      • Genmab
      • Actavis (acquired by Watson)
      • BrainStorm Cell Therapeutics
      • Merck Serono
      • Novartis
      • Oramed Pharmaceuticals
      • Regeneron Pharmaceuticals
      • Advaxis
      • Cell Cure Neurosciences
      • Chiesi Farmaceutici
      • Dyax
      • Genzyme
      • GlaxoSmithKline
      • Incyte
      • Ipsen
      • Janssen Biotech
      • K2M
    • Top partnering deals by royalty rate
      • Table Top deals by royalty rate 2010- 2018
    • Top revenue share partnering deals
      • Table Deals disclosing revenue share 2010- 2018
  • Royalty rate contract directory
    • Explore royalty rates within the deal contract document to gain greater insight
  • Appendices
    • Royalty rates in deals - by company A-Z
      • Abbott Laboratories
      • Abbvie
      • Ablynx
      • Abraxis BioScience
      • Acceleron Pharma
      • Actavis (acquired by Watson)
      • Actavis (name changed to Allergan)
      • Active Biomaterials
      • Acura Pharmaceuticals
      • Adamis Pharmaceuticals
      • Adeona Pharmaceuticals
      • Adlai Nortye
      • Aduro BioTech
      • Advanced Dosage Forms
      • Advaxis
      • Advirna
      • AEterna Zentaris
      • Afritex Medical Products
      • Agenus Bio
      • Agios Pharmaceuticals
      • Akebia Therapeutics
      • Alchemia
      • Alder Biopharmaceuticals
      • Alector
      • Alexza Pharmaceuticals
      • Alfa Wassermann
      • Allergan
      • Almirall
      • Alnylam Pharmaceuticals
      • Altman Enterprises
      • AltrazealTrading
      • Amarantus BioSciences
      • American Type Culture Collection (ATCC)
      • Amgen
      • Amherst Pharmaceuticals
      • Amorfix Life Sciences
      • Ampio Pharmaceuticals
      • Amylin Pharmaceuticals
      • Amyris
      • AnaBios
      • Antibe Therapeutics
      • Antigen Express
      • Apricus Biosciences
      • Aradigm
      • Aratana Therapeutics
      • Arch Pharmalabs
      • Ardelyx
      • Arena Pharmaceuticals
      • Assembly Biosciences
      • Astellas Pharma
      • Astellas Pharma Europe
      • Asterias Biotherapeutics
      • AstraZeneca
      • Athenex
      • Atossa Genetics
      • Audeo Oncology
      • Aurigene Discovery Technologies
      • AVEO Oncology
      • Avita Medical
      • Azaya Therapeutics
      • Azure Biotech
      • BASF
      • Baxter International
      • Bayer Healthcare
      • Bayer Innovation
      • Baylor Research Institute
      • Belgian Volition
      • Bellerophon Therapeutics
      • Besins Healthcare
      • Beth Israel Deaconess Medical Center
      • BIND Biosciences
      • Biogen
      • BioGene Technology
      • BioInvent
      • BiolineRX
      • BioMarin Pharmaceutical
      • BioNovion
      • BioNTech
      • Biopharmex
      • BiopharmX
      • BioPorto
      • Bioprocess Capital Ventures
      • BioProspect
      • Biostem US
      • Biotechnology Value Fund
      • Biotech Investment
      • BioTime Acquisition
      • Bioton
      • Biovail
      • BioZone Laboratories
      • BioZone Pharmaceuticals
      • Bluebird Bio
      • BMV Medica
      • Boehringer Ingelheim
      • Braeburn Pharmaceuticals
      • BrainStorm Cell Therapeutics
      • Breathtec BioMedical
      • Caleco Pharma
      • Can-Fite BioPharma
      • CanniMed Therapeutics
      • Cardigant Medical
      • Cardium Therapeutics
      • Cary Pharmaceuticals
      • Catalent Pharma Solutions
      • Celdara Medical
      • Celgene
      • Cell Cure Neurosciences
      • Celyad
      • Cel Sci
      • Cerus
      • Chi-Med
      • Chiesi Farmaceutici
      • Chong Kun Dang
      • Cimtech
      • Cipher Pharmaceuticals
      • Clalit Health Services
      • Clal Biotech
      • Clemson University
      • Cleveland BioLabs
      • Clinigen
      • CMIC
      • Cocrystal Pharma
      • Cohen-McNiece Foundation
      • Coherus Biosciences
      • Colby Pharmaceuticals
      • Columbia Laboratories
      • Columbia University
      • Common Sense
      • Concile
      • ContraFect
      • Coronado Biosciences
      • CRISPR Therapeutics
      • Crucell
      • CTT Pharmaceutical
      • CureTech
      • Curis
      • CURx Pharmaceuticals
      • Cutanea Life Sciences
      • Cypress Bioscience
      • Cytori Therapeutics
      • Daewoong Pharmaceutical
      • Dana-Farber Cancer Institute
      • Dance Biopharm
      • Defiante Farmaceutica
      • Denali Therapeutics
      • Derma Sciences
      • Dicerna Pharmaceuticals
      • DNA Biomedical Solutions
      • Dr. Falk Pharma
      • Dr. Reddy's Laboratories
      • Drugs for Neglected Diseases Initiative
      • DS Healthcare
      • Duke University
      • Dyax
      • Eagle Pharmaceuticals (US)
      • Easton Pharmaceuticals
      • Echo Therapeutics
      • Ecology Coatings
      • Eddingpharm
      • Eisai
      • Elencee
      • Elite Pharmaceuticals
      • Eli Lilly
      • Emergent BioSolutions
      • Emory University
      • Endocyte
      • Endo Pharmaceuticals
      • Entera Bio
      • Entest BioMedical
      • EnWave
      • Epizyme
      • Epocal
      • Eternity Healthcare
      • Eureka Genomics
      • EUSA Pharma
      • Evolva
      • Exelixis
      • Eyevance
      • Fairview Health System
      • FasTrack Pharmaceuticals
      • Fibrocell Science
      • Fibrogen
      • Forest Laboratories
      • Fosun Pharmaceutical
      • Fresenius Kabi Pharmaceuticals
      • FusionVax
      • Galapagos
      • Galmed Pharmaceuticals
      • Genentech
      • Generex Biotechnology
      • Genmab
      • Gentium
      • Genzyme
      • Geron
      • Gilead Sciences
      • GlaxoSmithKline
      • Glenmark Generics Inc USA
      • Glenmark Pharmaceuticals
      • Government of Israel
      • Grifols
      • Hail First Pharma
      • Hainan Sihuan Pharmaceutical
      • Halozyme Therapeutics
      • Hansen Medical
      • Health Canada
      • Health Discovery
      • Heat Biologics
      • Hefei Life Science
      • Hefei Tianhui Incubation of Technologies
      • HemoCleanse
      • HIBM Research Group
      • Hikma Pharmaceuticals
      • Hoffmann La Roche
      • Horizon Pharma Inc
      • HyperGenomics
      • Icahn School of Medicine at Mount Sinai
      • Ice + Jam
      • IDC-GP Pharm
      • Idorsia
      • Immunovative Therapies
      • Impax Laboratories
      • Imprimis Pharmaceuticals
      • INAP
      • Incuron
      • Incyte
      • Infinity Pharmaceuticals
      • Innate Pharma
      • Innocoll
      • Innovus Pharmaceuticals
      • INO Therapeutics
      • Inspiration Biopharmaceuticals
      • Instrumentation Laboratory
      • IntelGenx
      • IntelliCell BioSciences
      • Intellikine
      • Internet Marketing Consortium
      • Intrexon
      • Intuitive Surgical
      • Invekra
      • Inverness Medical Innovations
      • Ipsen
      • Ironwood Pharmaceuticals
      • Israeli National Authority for Technological Innovation
      • Jaguar Health
      • Janssen Biotech
      • Janssen Pharmaceuticals
      • JFC Technologies
      • Jiangsu Lianhuan Pharmaceuticals
      • Juniper Pharmaceuticals
      • K2M
      • KaloBios Pharmaceuticals
      • Kensey Nash
      • Kieran Murphy
      • Kinetic Concepts
      • Knight Therapeutics
      • Kraig Biocraft Laboratories
      • Kwang Dong Pharmaceutical
      • Kyowa Hakko Kirin
      • Laboratories Acbel
      • Legend Biotech
      • LFB Biotechnologies
      • Ligand Pharmaceuticals
      • Lubrizol
      • Lumenis
      • Lundbeck
      • MabCure
      • Macrogenics
      • MainPointe
      • Marvanal
      • Marv Enterprises
      • Massachusetts General Hospital
      • McComb Foundation
      • Meda
      • Medica
      • Medical Technologies Innovation Asia
      • Medica Avante
      • MediGene
      • MedImmune
      • Medivation
      • Medivir
      • Medovex
      • Melmed
      • Memory Dx
      • Merck and Co
      • Merck KGaA
      • Merck Serono
      • Merus
      • Micromet
      • Mikah Pharma
      • Millennium
      • Ministry of Health, Labor and Welfare
      • Miraculins
      • Moderna Therapeutics
      • MorphoSys
      • MultiCell Immunotherapeutics
      • Munich Leukemia Laboratory
      • NantCell
      • NantWorks
      • Napo Pharmaceuticals
      • Natac Biotech
      • Natco Pharmaceuticals
      • Neogenomics
      • Nephrogenex
      • Nephros
      • NeuroSigma
      • NeuroVive Pharmaceutical
      • NeuroVive Pharmaceutical Asia
      • New York University
      • NexMed
      • Nexvet
      • NGM Biopharmaceuticals
      • Nicox
      • Nordic Bioscience
      • Novadaq Technologies
      • NovaDel Pharma
      • Novartis
      • Novartis Vaccines and Diagnostics
      • Novus Biologicals
      • Nucorion
      • Nutech Medical
      • NutraOrigin
      • Nymox Pharmaceutical
      • Oculus Innovative Sciences
      • Omeros
      • Oncolytics Biotech
      • OncoMed Pharmaceuticals
      • One Way Liver Genomics (OWL)
      • Onyx Pharmaceuticals
      • Opexa Therapeutics
      • Oragenics
      • Oramed Pharmaceuticals
      • Orexigen Therapeutics
      • Organovo
      • Orion
      • Orox Pharmaceuticals
      • OrthoCyte
      • Otsuka
      • OvaMed
      • Oxis Biotech
      • OxySure Systems
      • Pan-Provincial Vaccine Enterprise
      • Parnell Pharmaceutical Holdings
      • Par Pharmaceutical
      • PDL BioPharma
      • Penwest Pharmaceuticals
      • Perugia University
      • Pfizer
      • Pharmacyclics
      • PharmaNova
      • Phosphagenics
      • Phusion Laboratoies
      • Phyto Nutricare
      • Pipex Pharmaceuticals
      • Plandai Biotechnology
      • Pluristem Therapeutics
      • Portola Pharmaceuticals
      • Pozen
      • PreMD
      • Premier Biomedical
      • Professional Compounding Centers of America
      • Progenics Pharmaceuticals
      • Prometic Life Sciences
      • ProQR Therapeutics
      • Prosidion
      • Protalix BioTherapeutics
      • Proteonomix
      • Prothena Biosciences
      • ProtoKinetix
      • Puma Biotechnology
      • QRxPharma
      • Quick Med Technologies
      • Quigley Corporation
      • Reata Pharmaceuticals
      • Recordati
      • Recro Pharma
      • RedHill Biopharma
      • RegenaStem
      • Regeneron Pharmaceuticals
      • Relmada Therapeutics
      • Resarci Therapeutics
      • Retrophin
      • REVO Biologics
      • RNL Bio
      • Roche
      • Rockefeller University
      • Roivant Sciences
      • Royalty Pharma
      • RST Biomedikal Sanayi
      • Ruthigen
      • RXi Pharmaceuticals
      • S2 Therapeutics
      • Sage Therapeutics
      • Salix Pharmaceuticals
      • Sam Amer
      • Sandoz
      • Sanofi-Aventis
      • Sanofi-Pasteur
      • Sanofi
      • Santarus
      • Sarepta Therapeutics
      • SA Pathology
      • Seattle Genetics
      • Seelos Therapeutics
      • Senetek
      • Sermonix Pharmaceutical
      • Sheba Medical Center
      • Shenzhen BioScien Pharmaceuticals
      • Shionogi
      • Shire Pharmaceuticals
      • Shore Therapeutics
      • Sigma-Tau
      • Sinclair Pharmaceuticals
      • Sinobiopharma
      • Sinopharm
      • Skinvera
      • Skyline Diagnostics
      • Soliance
      • Soligenix
      • Sorrento Therapeutics
      • Spectranetics
      • Spencer Pharmaceutical
      • Spinal USA
      • St. Jude Children's Research Hospital
      • Stellar Biotechnologies
      • Strongbridge Biopharma
      • St Jude Medical
      • Sunesis Pharmaceuticals
      • SuperNova Diagnostics
      • Swedish Orphan Biovitrum
      • Symbollon
      • Synergy Strips
      • Syntopix
      • Taiba
      • Takeda Pharmaceutical
      • Tauriga Sciences
      • TB Alliance
      • Technion Research and Development Foundation
      • TetraLogic Pharmaceuticals
      • Teva Pharmaceutical Industries
      • Texas A&M University
      • Theravance
      • The Regents of the University of California
      • Threshold Pharmaceuticals
      • TiGenix
      • Titterington Veterinary Services
      • Tiziana Life Sciences
      • TONIX Pharmaceuticals
      • Tramorgan
      • Transgene
      • Trellis Bioscience
      • Trevena
      • Trimedyne
      • Trimeris
      • TrovaGene
      • TTFactor
      • Ultragenyx Pharmaceuticals
      • Uluru
      • Unigene Laboratories
      • UniQure
      • University of Alberta
      • University of California
      • University of Central Florida Research Foundation
      • University of Colorado
      • University of Florida Research Foundation
      • University of Missouri
      • University of Notre of Dame
      • University of Pennsylvania
      • University of Western Sydney
      • UOP
      • Upstream Peripheral Technologies
      • Valeant Pharmaceuticals
      • ValiPharma
      • Vanderbilt University
      • Vaxent
      • VBL Therapeutics (dba)
      • Veloxis Pharmaceuticals
      • Veracyte
      • Verenium
      • VeroScience
      • Vertex Pharmaceuticals
      • ViiV Healthcare
      • Virbac
      • Viropharma
      • VolitionRX
      • Voyager Therapeutics
      • Vyrix Pharmaceuticals
      • Watson Pharmaceuticals
      • Wisconsin Alumni Research Foundation
      • Xencor
      • XTL Biopharmaceuticals
      • Xynomic Pharmaceuticals
      • Yale University
      • Yeda Research and Development Company
      • Yeugnam University
      • Zalicus
      • Zenitech
      • Ziopharm Oncology
      • ZS Pharma
    • Royalty rates in deals - by therapy area
      • Anaesthetics
      • Breast
      • Cardiovascular
      • Cardiomyopathy (heart muscle disease)
      • Congestive heart failure
      • Coronary artery disease
      • Hypercholesterolemia
      • Hypertension
      • Myocardial Infarction
      • Thrombus (blood clot)
      • Central Nervous System
      • Epilepsy
      • Bacterial
      • Migraine
      • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
      • Multiple sclerosis
      • Neuropathy
      • Pain
      • Fibromyalgia
      • Parkinson's disease
      • Spinal cord
      • Traumatic Brain Injury
      • Dental
      • Oral health
      • Dermatology
      • Acne
      • Actinic keratosis
      • Angioedema
      • Cosmetics
      • Itching
      • Psoriasis
      • Wound healing
      • Gastrointestinal
      • Hemorrhoids (haemorrhoids)
      • Crohn's disease
      • Ulcerative colitis
      • Irritable bowel syndrome
      • Gastric ulcer
      • Abdominal pain
      • Bowel movement
      • Constipation
      • Genetic disorders
      • Cystic Fibrosis (CF)
      • Hereditary angioedema
      • Huntington's disease
      • Rare genetic disorders
      • Sickle cell disease
      • Genitourinary
      • Acute kidney injury
      • Amyloidosis
      • Chronic kidney disease (CKD)
      • Renal failure
      • Gynaecology
      • Human papillomavirus (HPV)
      • Infertility
      • Menopause
      • Hematology
      • Anemia
      • Hemophilia
      • Thalassemia
      • Hospital care
      • Poisoning
      • Surgery
      • Orthopedics
      • Transplantation
      • Immunology
      • Other autoimmune
      • Inflammation
      • Systemic lupus erythematosus
      • Infectives
      • Bacterial
      • Anthrax
      • Group A Streptococcus
      • Methicillin-resistant Staphylococcus aureus (MRSA)
      • Mycobacterium avium
      • Pseudomonas aeruginosa
      • Tuberculosis (TB)
      • Viral
      • Common cold
      • B
      • C
      • HIV
      • Influenza
      • Metabolic
      • Diabetes
      • Type 2
      • Growth hormone disorders
      • Nonalcoholic steatohepatitis (NASH)
      • Lysosomal storage disorders
      • Nutrition and vitamins
      • Thyroid disease
      • Musculoskeletal
      • Ankylosing spondylitis
      • Osteoarthritis
      • Psoriatic arthritis
      • Rheumatoid arthritis
      • Knee
      • Muscular dystrophy
      • Osteoporosis
      • Oncology
      • Bone cancer
      • Brain cancer
      • Breast cancer
      • Cervical cancer
      • Colorectal cancer
      • Gastric cancer
      • Head and neck cancer
      • Kidney cancer
      • Leukemia
      • Acute myelogenous leukemia
      • Chronic lymphocytic leukemia
      • Liver cancer
      • Non small cell lung cancer
      • Lymphoma
      • Non Hodgkin's lymphoma
      • Melanoma
      • Multiple myeloma
      • Ovarian cancer
      • Pancreatic cancer
      • Prostate cancer
      • Renal cell carcinoma
      • Solid tumors
      • Cancer pain
      • Chemotherapy
      • Thyroid cancer
      • Ophthalmics
      • Age-related macular degeneration
      • Cataracts
      • Conjunctivitis
      • Uveitis
      • Orphan disease
      • Psychiatry
      • Post traumatic stress disorder
      • Attention deficit hyperactivity disorder
      • Alzheimers
      • Depression
      • Moderate
      • Severe
      • Schizophrenia
      • Insomnia
      • Narcolepsy
      • Alcohol
      • Obesity
      • Respiratory
      • Asthma
      • Chronic obstructive pulmonary disease
      • Emphysema
      • Pneumonia
      • Pulmonary arterial hypertension
      • Sexual Health
      • Sexual dysfunction
    • Royalty rates in deals - by stage of development at signing
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Royalty rates in deals - by technology type
      • Analysis
      • Antibiotics
      • Antibodies
      • Antibody-drug conjugate
      • Bispecific antibodies
      • Monoclonal antibodies
      • Humanized mAb
      • Human mAb
      • Assays
      • Biodefense
      • Bioinformatics
      • Biological compounds
      • Biomarkers
      • Biomaterials
      • Bioprocessing
      • Biosimilars/Bio-betters
      • Blood products
      • Cell culture
      • Clinical testing
      • CRISPR
      • Devices
      • Diagnostics
      • Companion
      • Imaging
      • In vitro diagnostics
      • Molecular diagnostics
      • Prognostics
      • Discovery tools
      • Drug delivery
      • Bioavailability
      • Implantable
      • Oral delivery
      • Delayed release
      • Rapid release
      • Infusion
      • Injectable
      • Pro-drug
      • Targeted
      • Topical
      • Transdermal
      • Transmucosal
      • Inhaled
      • Ocular
      • Enabling technology
      • Enviromental
      • Epigenetics
      • Equipment
      • Gene therapy
      • Genomics
      • Implant
      • Industrial chemicals
      • Nanotechnology
      • Natural product
      • Packaging
      • Peptides
      • Personalised medicine
      • Processes
      • Proteomics
      • Radio/Chemo-therapy
      • Recombinant DNA
      • Regenerative medicine
      • Anti-aging
      • Cell therapy
      • Stem cells
      • Research services
      • Research supplies
      • RNA therapeutics
      • Screening
      • Small molecules
      • Software tools
      • Transgenics
      • Vaccines
    • Royalty rate references
    • Resources
      • Table Online partnering resources
    • Deal type definitions
      • Table Deal type definitions
    • Example royalty rate deal contract document
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from CurrentPartnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report